Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Septerna, Inc. (NASDAQ:SEPN) have been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $45.8889.

SEPN has been the subject of a number of research reports. Stifel Nicolaus assumed coverage on Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 price target for the company. Wall Street Zen cut Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Guggenheim decreased their target price on Septerna from $52.00 to $45.00 and set a “buy” rating for the company in a report on Wednesday, July 1st. Truist Financial upped their target price on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Septerna in a report on Wednesday, July 1st.

Septerna Trading Up 7.1%

Shares of Septerna stock opened at $35.83 on Friday. Septerna has a 12-month low of $10.62 and a 12-month high of $37.99. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of -44.23 and a beta of 2.29. The firm’s 50 day simple moving average is $30.45 and its two-hundred day simple moving average is $27.77.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The business had revenue of $26.52 million during the quarter, compared to the consensus estimate of $16.98 million. On average, sell-side analysts predict that Septerna will post -1.59 EPS for the current fiscal year.

Insider Activity

In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total value of $97,360.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at $4,240,247.06. This represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Samira Shaikhly sold 2,178 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the transaction, the insider directly owned 793 shares of the company’s stock, valued at approximately $27,897.74. This trade represents a 73.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 48,494 shares of company stock valued at $1,566,751 in the last ninety days. Insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

Several institutional investors and hedge funds have recently modified their holdings of the stock. Group One Trading LLC grew its holdings in Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after acquiring an additional 8,955 shares during the period. Global Retirement Partners LLC acquired a new position in Septerna in the fourth quarter valued at approximately $35,000. Russell Investments Group Ltd. purchased a new stake in Septerna in the 3rd quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Septerna in the 4th quarter worth approximately $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Septerna during the 4th quarter worth approximately $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.